Conditions

New retrospective study results compare the two most largely prescribed antidiabetic medication classes in addition to metformin, to determine the impact on the incidence of CV events in patients with T2DM. Dipeptidyl-peptidase-4 inhibitors (DPP-4i) and sulphonylureas (sulfonylureas in the US) (SU) are two of the most prescribed medication to date …

A comprehensive study reveals the importance of ophthalmologic and otologic care in patients with T2DM due to the association of increased risks for cardiovascular events in those with a decline in vision and hearing abilities. It is known that patients with type 2 diabetes mellitus (T2DM) have an increased risk …

Many drugs have CV benefits, reduce HA1c, have metabolic effects, and improve NASH/NAFLD in people with diabetes. Still, pioglitazone, an SGLT2 inhibitor, seems to be one of the cheap drugs and has many functions with more significant benefits than risk. There are a lot of CV trials conducted like the …

In the SWEET project experience, a large cohort of patients was started on either an insulin pump, glucose sensor, or both to compare the HbA1c levels and weight gain while on their new therapy. Many health complications can arise from diabetes, especially for adolescents and children with type 1 diabetes, …

A retrograde cohort study suggests that metabolic and acid base parameters may be useful in differentiating typical diabetic ketoacidosis DKA from Hyperglycemic Ketoacidosis related to cannabis hyperemesis syndrome in patients with type 1 Diabetes After the legalization of cannabis in Colorado and increasing its use among patients with type 1 …

Data suggest that personalizing therapy may ease the burden of diabetic complications and prevent diabetes in the future generation.

There is strong evidence that circulating markers of systemic inflammation can predict long-term cognitive decline among older people with type 2 diabetes.

Data analysis suggests that weight changes during weight loss attempts may raise the risk of cardiovascular disease and mortality in people with type 2 diabetes. 

In the SWEET project experience, a large cohort of patients was started on either an insulin pump, glucose sensor, or both to compare the HbA1c levels and weight gain while on their new therapy.

Verapamil might serve as a potential breakthrough allowing type one diabetes patients to produce their insulin.